Peter Hulick to Male
This is a "connection" page, showing publications Peter Hulick has written about Male.
Connection Strength
0.274
-
Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network. Genet Test Mol Biomarkers. 2021 Feb; 25(2):152-160.
Score: 0.040
-
Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer. 2014 Dec; 13(4):527-36.
Score: 0.026
-
Multicenter development and validation of a risk stratification tool for ward patients. Am J Respir Crit Care Med. 2014 Sep 15; 190(6):649-55.
Score: 0.013
-
Effects of Social Determinants and Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions. Ann Fam Med. 2024 Nov 01; 21(Suppl 3).
Score: 0.013
-
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022 09; 25(3):422-430.
Score: 0.011
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
Score: 0.011
-
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. Prostate. 2021 09; 81(13):1002-1008.
Score: 0.010
-
Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB. J Med Genet. 2022 03; 59(3):243-247.
Score: 0.010
-
Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank. Int J Cancer. 2021 04 01; 148(7):1658-1664.
Score: 0.010
-
Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.
Score: 0.010
-
Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations. Am J Hum Genet. 2020 10 01; 107(4):727-742.
Score: 0.010
-
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. Br J Cancer. 2020 10; 123(9):1356-1359.
Score: 0.010
-
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020 08 01; 6(8):1218-1230.
Score: 0.010
-
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
Score: 0.009
-
De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. Eur J Hum Genet. 2019 07; 27(7):1081-1089.
Score: 0.009
-
Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
Score: 0.009
-
Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics. 2018 03; 19(4):321-331.
Score: 0.008
-
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
Score: 0.008
-
History repeats itself: the family medication history and pharmacogenomics. Pharmacogenomics. 2016 05; 17(7):669-78.
Score: 0.007
-
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet. 2016 05 05; 98(5):830-842.
Score: 0.007
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
Score: 0.007
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.007
-
Diagnostic Exome Sequencing Identifies a Novel Gene, EMILIN1, Associated with Autosomal-Dominant Hereditary Connective Tissue Disease. Hum Mutat. 2016 Jan; 37(1):84-97.
Score: 0.007
-
Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar; 9(3):527-35.
Score: 0.006
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014 Sep; 66(3):489-99.
Score: 0.006